{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:28:58Z","timestamp":1792427338530,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1136\/ijgc-2023-004777","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T13:35:13Z","timestamp":1695994513000},"page":"1764-1770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anlotinib in patients with recurrent platinum resistant\/refractory ovarian cancer: a prospective, single arm, phase II study"],"prefix":"10.1016","volume":"33","author":[{"given":"Wenbin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5353-4821","authenticated-orcid":false,"given":"Boer","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004777_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004777_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"10.1136\/ijgc-2023-004777_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-022-01003-2","article-title":"Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases","volume":"15","author":"Han","year":"2022","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004777_bb0025","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.20517\/cdr.2022.13","article-title":"Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer","volume":"5","author":"Flynn","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1136\/ijgc-2023-004777_bb0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2009.24.1455","article-title":"Phase II clinical trial of Ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study","volume":"28","author":"De Geest","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamaoncol.2022.2253","article-title":"Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","article-title":"Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study","volume":"19","author":"Lan","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0065","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"10.1136\/ijgc-2023-004777_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","article-title":"Targeting angiogenesis in ovarian cancer","volume":"38","author":"Schmitt","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2023-004777_bb0075","article-title":"Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1B trial","volume":"3","author":"Lan","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1136\/ijgc-2023-004777_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/DDDT.S286529","article-title":"A retrospective observational study of Anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer","volume":"15","author":"Cui","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1136\/ijgc-2023-004777_bb0085","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.2147\/OTT.S268613","article-title":"Anlotinib as exploratory therapy for platinum-resistant ovarian cancer: a retrospective study on efficacy and safety","volume":"13","author":"Ni","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1136\/ijgc-2023-004777_bb0090","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"P53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2023-004777_bb0095","article-title":"P53 immunohistochemistry and mutation types mismatching in high-grade serous ovarian cancer","volume":"12","author":"Park","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1136\/ijgc-2023-004777_bb0100","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0105","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ijgc-00009577-200509000-00012","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004777_bb0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0120","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2015.04.009","article-title":"A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California phase II consortia","volume":"138","author":"Hirte","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2017.12.013","article-title":"A phase II study of apatinib in patients with recurrent epithelial ovarian cancer","volume":"148","author":"Miao","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0135","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1136\/ijgc-2023-004777_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"10.1136\/ijgc-2023-004777_bb0145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.20892\/j.issn.2095-3941.2019.0215","article-title":"Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFbeta1 pathways via off-VEGF signaling","volume":"17","author":"Zhang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1136\/ijgc-2023-004777_bb0150","article-title":"Anlotinib reverses multidrug resistance (MDR) in osteosarcoma by inhibiting P-glycoprotein (PGP1) function in vitro and in vivo","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1136\/ijgc-2023-004777_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2023-004777_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0165","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0170","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0175","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0090-8258(21)00758-7","article-title":"Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: a single-arm, open-label, phase II study","volume":"162","author":"Chen","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0180","doi-asserted-by":"crossref","first-page":"101767","DOI":"10.1016\/j.eclinm.2022.101767","article-title":"A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: efficacy and safety results from the phase II, multi-center ANNIE study","volume":"54","author":"Liu","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1136\/ijgc-2023-004777_bb0185","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.21037\/tcr.2016.07.45","article-title":"TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet.","volume":"5","author":"Oien","year":"2016","journal-title":"Transl Cancer Res"},{"key":"10.1136\/ijgc-2023-004777_bb0190","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2023-004777_bb0195","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.2147\/OTT.S257052","article-title":"Association of TP53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer","volume":"13","author":"Fang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1136\/ijgc-2023-004777_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01823-w","article-title":"Anlotinib plus Icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1136\/ijgc-2023-004777_bb0205","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1002\/cam4.3282","article-title":"Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: a single-center retrospective study","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"key":"10.1136\/ijgc-2023-004777_bb0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3747\/co.19.972","article-title":"Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents","volume":"19","author":"Larochelle","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1136\/ijgc-2023-004777_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","article-title":"Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial","volume":"10","author":"Rini","year":"2015","journal-title":"Target Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:00Z","timestamp":1753234140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24017870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1048891X24017870"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004777","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anlotinib in patients with recurrent platinum resistant\/refractory ovarian cancer: a prospective, single arm, phase II study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}